CTOs on the Move


 
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.my01.io
  • 400 Boul de Maisonneuve Ouest Suite 700
    Montréal, QC CAN H3A 1L4
  • Phone: 855.799.6901

Executives

Name Title Contact Details

Similar Companies

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.

Surge Medical

Surge Medical is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enlitic

Enlitic is focused on developing solutions that enhance clinical workflows, enable research and development, improve billing accuracy, and decrease risk. We`re not an AI company that only produces algorithms for detection and prioritization of specific diseases – point solutions. We`re a medical intelligence company that delivers solutions with a point; to enable better patient outcomes by enhancing what`s possible in data processes. We are working to eliminate inefficiencies in workflows and ensure medical information is more useful and more impactful for patient care.

Innercool Therapies

Innercool Therapies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sysmex

Sysmex America, Inc. distributes and supports automated `in vitro` diagnostic hematology, coagulation and urinalysis analyzers, reagents, and information systems for laboratories and healthcare facilities throughout the Western Hemisphere.? The company was formerly known as Sysmex Corporation Of America and changed its name to Sysmex America, Inc. in June 2003. The company was founded in 1979 and is based in Lincolnshire, Illinois. Sysmex America, Inc. operates as a subsidiary of Sysmex Corp.